Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

Niagen Bioscience CEO Robert Fried discusses the science of NAD, the problems with the supplement industry, and how his company is leading the way in anti-aging research.

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Executives from Niagen Bioscience, Pushly, and VidaCorp discuss brand evolution. Learn why authenticity, community, and AI are key to building a resilient brand.

Investing.com -- Niagen Bioscience Inc (NASDAQ: NAGE) stock rose 2% after the company announced an exclusive worldwide commercial license agreement with Norway’s Haukeland University Hospital to ...

Niagen Bioscience, Inc., the global authority on NAD+ with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15 th Annual London ...

View the latest Niagen Bioscience Inc. (NAGE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Niagen Bioscience Inc. has reached a significant milestone as its stock hit a 52-week high of 14.49 USD, with InvestingPro data showing the company maintains a "GREAT" overall financial health ...

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full ...

Niagen Bioscience CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutional investors throughout the conference.

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...